Press Releases

Date Headline
3/3/2022
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Mar. 3, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences during March:  Continue Reading
2/24/2022
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
 Summary
Enrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.  Continue Reading
2/8/2022
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Feb. 8, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial results after  Continue Reading
2/3/2022
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Feb. 3, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences.  Continue Reading
1/31/2022
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 31, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the closing of its previously announced underwritten public offering of 11,035,000 common  Continue Reading
1/26/2022
Zymeworks Announces Pricing of $100.0 Million Public Offering
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 26, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the pricing of its underwritten public offering of 9,160,000 common shares and, in lieu of  Continue Reading
1/26/2022
Zymeworks Announces Proposed Public Offering
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 26, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has commenced an underwritten public offering of its common shares and, in lieu of  Continue Reading
1/19/2022
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
 Summary
New Chair and CEO, Mr. Kenneth Galbraith , outlines strategic priorities for 2022 and 2023 across key clinical development activities for zanidatamab and ZW49, preclinical R&D pipeline, collaborations and partnerships Further changes to leadership team announced today in connection with Mr.  Continue Reading
1/15/2022
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 15, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE  Continue Reading
1/6/2022
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 6, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Klompas , Zymeworks’ Chief Operating Officer and Chief Financial Officer, will  Continue Reading
Displaying 11 - 20 of 21
Copyright 2022 , Zymeworks Inc.